Agent Studio reimagines the clinical trial lifecycle, automating slow, manual processes, removing barriers in the clinical process, andintroducing new ways to achieve clinical goals like never before. This first-of-its-kind, AI-powered, no-code platform lets you deployready-to-go agents trained as clinical development experts or create bespoke ones using your own data and expertise, unlockingendless possibilities.

In a rapidly changing research landscape, leaders at Takeda, Novartis, Sanofi, Daiichi Sankyo, and Medable share firsthand insights into how artificial intelligence is reshaping clinical trial operations.

This exclusive whitepaper explores how forward-thinking organizations are reimagining trial design, execution, and scaling to meet the demands of speed, precision, and patient-centricity across their entire portfolio.

‍

Traditionally, translations and language migration create significant bottlenecks on the path to trial study go-live. The process is traditionally manual, linear, and resource intensive. To address these challenges, Medable partnered with Lionbridge, a leading translation services company to compare the status quo translation process against an AI-enabled approach powered by both companies’ proprietary new AI tools.

A top-3 contract research organization (CRO) and a top-10 pharmaceutical company partnered with Medable to help accelerate the speed, scale, and standardization of their eCOA trials.

The two organizations had been hampered by lengthy configuration timelines, inconsistent designs across studies, and siloed processes between sponsors and their CRO partners.

By centralizing the sponsor’s preferred instruments and configurations into a reusable digital library, Medable enabled the CRO to rapidly accelerate its portfolio development and initiate new studies without starting them “from scratch.”

‍

Complete the form to get your copy of the case study and see how we enable rapid acceleration for CROs.

‍

Learn how digital tools ease oncology research for all stakeholders while accelerating the pace of research with this whitepaper.

‍

A top global clinical research organization (CRO) partnered with Medable to transform its approach to clinical trial building. Recognizing the inefficiencies in traditional build processes that often “take weeks,” the client leveraged Medable’s Studio platform with its latest AI capabilities to dramatically accelerate timelines, enhance transparency, and improve quality.

‍

‍

A top-10 global pharmaceutical company partnered with Medable for their pivotal Phase III diabetes study in the highly competitive market. Recognizing the inefficiencies in traditional study delivery and closeout processes, the company leveraged Medable’s expertise to accelerate timelines, enhance operational efficiency, and achieve a faster time to market for this high-profile therapy.

‍

When OpenAI unveiled ChatGPT in November 2022, it ignited unprecedented interest in artificial intelligence. Three years later, generative AI and machine learning have caused seismic shifts in industries worldwide. The pharmaceutical industry is not left out of this shift, with Roots Analysis reporting that they expect AI within clinical trials to grow at a compound annual growth rate of 16% through 2035. This growth is driven by belief in AI’s unique ability to process and analyze massive datasets at groundbreaking speeds, identifying patterns and generating insights that would be impossible to discover through traditional methods. By leveraging these capabilities, pharmaceutical companies hope to fundamentally reimagine core aspects of clinical trials, from initial design through final data analysis.

‍

A top-10 global pharmaceutical company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites and participants in Japan.

Recognizing Japan’s distinct regulatory, cultural, and logistical landscape, the company partnered with Medable todevelop an initiative to enhance the region’s patient and site experience.

‍

Medable’s 2024 was a year of exceeding key milestones and helping our customers reach new heights.

Take a look at the difference Medable has made with our year-end impact report.

‍

‍

‍

‍

‍

A top-10 global pharmaceutical company came to Medable looking to standardize and scale their weight management trials. The trial was driven by a master protocol with multiple sub-studies across 70+ research sites.

The partner was concerned about the participant and site experience, particularly participant enrollment and study startup timelines, as the trial required participants to enroll through the master protocol before enrolling into a sub-study.

Read ahead to see how Medable accomplished this, beat the forecasted FPI date, and more.

DCT and digital elementsare now the new normal. But what exactly does "digital" or "decentralized" mean in the context of clinical trials?

A panel of industry experts from Sanofi, Bayer, and the Clinical Trials Transformation Initiative (CTTI) recently came together to discuss the evolution of DCTs and share their experiences.

‍